✦ LIBER ✦

Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales

✍ Scribed by Pierre N Tariot; Rebekah Loy; J.Michael Ryan; Anton Porsteinsson; Saleem Ismail

Book ID: 114176124
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 239 KB
Volume: 54
Category: Article
ISSN: 0169-409X
DOI: 10.1016/s0169-409x(02)00153-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacotherapy in Alzheimer's disease:

Pharmacotherapy in Alzheimer's disease: Basis and rationale

✍ Narang, Prem K.; Cutler, Neal R. 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 975 KB

Progress in pharmacotherapy of Alzheimer

Progress in pharmacotherapy of Alzheimer's disease: Symptomatic stabilization with cholinesterase inhibitors

✍ E. Giacobini 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 324 KB

Symptomatic and neuroprotective effects

Symptomatic and neuroprotective effects of dopamine agonists in Parkinson's disease

✍ P. Jenner 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 145 KB

A preclinical view of cholinesterase inh

A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

✍ Paul T. Francis; Agneta Nordberg; Steven E. Arnold 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 244 KB

Antioxidant neuroprotection in Alzheimer

Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach

✍ Christian Behl; Bernd Moosmann 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Nicotinic Acetylcholine Receptor Signall

Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

✍ Buckingham, Steven D. (author);Jones, Andrew K. (author);Brown, Laurence A. (aut 📂 Article 📅 2009 🏛 American Society for Pharmacology and Experimental 🌐 English ⚖ 423 KB